Ol'binskaia L I, Vartanova O A, Khapaev B A
Ter Arkh. 1994;66(12):13-6.
A 4-week course of dilren under clinical, bicycle exercise, ECG, echo-CG control and 24-hour monitoring of AP was given to 19 subjects with essential hypertension stage I-II and ischemic heart disease. A single dose of the drug (300 mg/day) diminished hypertension and angina pectoris in 79 and 63% of the patients, respectively. A 4-week dilren produced a 10-11% decrease in the total peripheral vascular resistance, prolonged P-Q interval by 0.01-0.02 sec without atrioventricular block in 26% of the patients, reduced AP measured according to Korotkov by 14.2/10.5 mm Hg (in awake patients by 12.8/8.4 mm Hg, in sleeping ones by 8.6/4.5 mm Hg without changes in 24-h AP curve). Side effects occurred in 5.3% of the cases and were overcome without discontinuation of the treatment.
对19例I-II期原发性高血压合并缺血性心脏病患者，给予为期4周的地尔硫䓬治疗，治疗过程中进行临床、自行车运动、心电图、超声心动图监测及24小时血压监测。单次给药剂量为300mg/天，分别使79%和63%的患者高血压和心绞痛症状减轻。连续服用4周地尔硫䓬后，总外周血管阻力降低10 - 11%，26%的患者P-Q间期延长0.01 - 0.02秒，但无房室传导阻滞，根据柯氏音测量的血压降低14.2/10.5mmHg（清醒患者降低12.8/8.4mmHg，睡眠患者降低8.6/4.5mmHg，24小时血压曲线无变化）。5.3%的患者出现副作用，且无需停药即可克服。
